The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.

@article{Tucker2008TheDA,
  title={The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.},
  author={Thomas J. Tucker and Sandeep Saggar and John T Sisko and Robert M Tynebor and Theresa M. Williams and Peter J. Felock and Jessica A. Flynn and Ming-tain Lai and Yuexia Liang and Georgia B. McGaughey and Meiquing Liu and Mike C. Miller and Gregory Moyer and Vandna Munshi and Rebecca A Perlow-Poehnelt and Sridhar G Prasad and Rosa Ma S{\'a}nchez and Maricel Torrent and Joseph P Vacca and Bang-Lin Wan and Youwei Yan},
  journal={Bioorganic & medicinal chemistry letters},
  year={2008},
  volume={18 9},
  pages={2959-66}
}
Using a combination of traditional Medicinal Chemistry/SAR analysis, crystallography, and molecular modeling, we have designed and synthesized a series of novel, highly potent NNRTIs that possess broad antiviral activity against a number of key clinical mutations.